Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts

In Vivo

Volumn 17, Issue 1, 2003, Pages 23-28

  Egawa, Tomohisa ^a   Kubota, Tetsuro ^a   Suto, Akihiko ^a   Otani, Yoshihide ^a   Furukawa, Toshiharu ^a   Saikawa, Yoshiro ^a   Watanabe, Masahiko ^a   Kumai, Koichiro ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Breast cancer; Combination therapy; Docetaxel; Doxorubicin; In vivo; P glycoprotein; Synergism

Indexed keywords

DOCETAXEL; DOXORUBICIN; GLYCOPROTEIN P; TAMOXIFEN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRAFT; CANCER GROWTH; CARCINOMA CELL; CELL STRAIN; CELL STRAIN MCF 7; CLINICAL ARTICLE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 0037241547     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Carter SK: Cancer treatment today and its impact on drug development, with special emphasis on its Phase II clinical trial. J Natl Cancer Inst 57: 235-244, 1976.
2. Adachi I, Watanabe T, Takashima S, Narabayasbi M, Horikoshi N, Aoyama H and Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73: 210-216, 1996.
3. Bonneterre J, Spielman M, Guastalla J-P, Marty M, Viens P, Chollet, P, Roche H, Fumoleau P, Mauriac L, Bourgeois H, Namer M, Bergerat JP, Misset JL, Trandafir L and Mahjoubi M: Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: The French compassionate use programme experience. Eur J Cancer 35: 1413-1419, 1999.
4. Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E and Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995.
5. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel, RG, Ravdin PM, Holmes FA, Rahmian, Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN and Burris HA III: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16: 3362-3368, 1998.
6. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, Von Minckwitz G, Korec S, Sininionds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzon M, Murawsky M, Alakl M and Riva A: Prospective randomized trials of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2350, 1999.
7. Nabholtz JM, Semi HJ, Bezwoda WR, Melnychuk D, Deschenes L, Dourna J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M and Aapro M: Prospective randomized trials of docetaxel versus mitomycin plus venoblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413-1424, 1999.
8. Soule HD, Vazguez J, Long A, Albert S and Brennan M: Human cell line from pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973.
9. Kubota T, Kubouchi K, Koh J, Enomoto K, Ishibiki K and Abe O: Human breast carcinoma (MCF-7) serially transplanted into nude mice. Jpn J Surg 13: 381-383, 1983.
10. Giovanella BC, Stehlin JS and Williams U Jr: Heterotransplantation of human malignant tumors in "nude" thymusless mice. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J Natl Cancer Inst 52: 921-930, 1974.
11. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM and Abott BJ: Protocols for screening chemical agents and natural products and other biological systems, 3rd ed. Cancer Chemother Rep (Part 3) 3: pp1-103, 1972.
12. Egawa T, Kubota T, Suto A, Otani Y, Furukawa T, Watanabe M, Kumai K and Kitajima M: Docetaxel enhances the cytotoxicity of anthracyclines by increasing intracellular drug, accumulation. Oncology Rep 9: 777-781, 2002.
13. Egawa T, Kubota T, Furukawa T, Otani Y, Watanabe M, Furukawa T, Kumai K and Kitajima M: Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner. Anticancer Res 21(4A): 2597-2600, 2001.
14. Juliano RI and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 455: 152-162 1976.
15. Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman NW and Pastan I: Isolation of hunian mdr DNA sequence amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83: 4538-4542, 1986.
16. Gerlach JE, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL and Ling V: Homology between P-glycoprotein and a bacterial haemolysin transport protein and a haemolysin transport protein suggests a model for multidrug resistance. Nature 324: 485-489, 1986.
17. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM and Roninson IB: Internal duplication and homology with bacterial transport protein in the mdr1 (P-glycoprotein) gene from multidrug-resistance human cells. Cell 47: 381-389, 1986.
18. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM and Pastan I: The human multidrug resistance (mdr1) gene. J Biol Chem 262: 505-508, 1987.
19. Tsuruo T: Mechanism of multidrug resistance and implication for therapy. Jpn J Cancer Res 79: 285-296, 1988.
20. Kubota T, Ishibiki K and Abe O: The clinical usefulness of human xenografts in nude mice. Prog Clin Biol Res 276: 213-225, 1988.
21. Kubota T, Matsuzaki WS, Hoshlya Y, Watanabe M, Kitajima M, Asanuma F, Yamada Y and Koh J: Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol 64(2): 115-121, 1997.
22. Komuro Y, Udagawa Y, Susumo N, Aoki D, Kubota T and Nozawa S: Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin. Jpn J Cancer Res 92: 1241-1250, 2001.